SO Moderna spiked from roughly $19.07 to $28 est. in less than 45 minutes after rumors broke into confirmations ending with headlines as Mordova has officially announced a vaccination for COVID-19 has been developed yet with months of red tape ahead of us (still have yet to undergo animal testing, clinical trials, human testing, then once the vaccination has been...
Novavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is.
Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you...
VXL is the volume leader on TSX-V today on the news of Coronavirus vaccine patent application.
+21.74% so far. Likely held down by warrant sellers but could be a serious runner once they are out.
$12M mkt cap is cheap compared to other biomed stocks that ran on Coronavirus related news.
Very decent float at 89M shares.
This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019).
Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com
Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com
Is this a good investment? If the vaccination is successful and/or coronavirus outbreak...
NNVC news
Flu vaccine makers' stocks jump following the outbreak of coronavirus from China.
World Health Organization accelerates diagnostics, vaccines, therapeutics for coronavirus.
There are 2 main stocks trading on heavy volume caused directly by this new possible pandemic:
CODX
NNVC
PCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines
Oslo (Norway), 21 January 2020 – PCI Biotech OSL:PCIB , a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with...
OSL:PCIB
www.netfonds.no
Oslo (Norway), 2 May 2019 . PCI Biotech ( OSL:PCIB ), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fima_Vacc_ Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4...
